Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03526549 · ClinicalTrials.gov registry record · Phase 3
Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)
A Phase 3 study of Cellulite and Edematous Fibrosclerotic Panniculopathy, sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 483
- Enrollment target
- 20
- Study locations
NCT03526549 is a Phase 3 study of Cellulite and Edematous Fibrosclerotic Panniculopathy that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 483 participants, above the 76-participant average among 5 other Cellulite trials with a reported enrollment target (536% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT03526549, a Phase 3 study of Cellulite and Edematous Fibrosclerotic Panniculopathy, has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 483 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3b, Open-Label Extension Study to evaluate safety and how long response of EN3835 (Collagenase Clostridium Histolyticum \[CCH\]-aaes) lasts in the treatment of Cellulite.
Conditions Studied
Interventions
- OTHER Observation
- BIOLOGICAL CCH-aaes
Study Locations (20)
California
- Endo Clinical Trial Site #14 - Encinitas
- Endo Clinical Trial Site #9 - Long Beach
- Endo Clinical Trial Site #35 - Murrieta
- Endo Clinical Trial Site #42 - Newport Beach
- Endo Clinical Trial Site #17 - Oceanside
- Endo Clinical Trial Site #39 - San Diego
Florida
- Endo Clinical Trial Site #38 - Boca Raton
- Endo Clinical Trial Site #8 - Coral Gables
- Endo Clinical Trial Site #40 - Largo
- Endo Clinical Trial Site #27 - Miami
- Endo Clinical Trial Site #36 - Miami
Arizona
- Endo Clinical Trial Site #3 - Glendale
- Endo Clinical Trial Site #11 - Scottsdale
Arkansas
- Endo Clinical Trial Site #41 - North Little Rock
Colorado
- Endo Clinical Trial Site #23 - Greenwood Village
Georgia
- Endo Clinical Trial Site #20 - Snellville
Idaho
- Endo Clinical Trial Site #19 - Meridian
Illinois
- Endo Clinical Trial Site #34 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 483 participants |
| Start Date | 2018-04-26 |
| Est. Completion | 2021-10-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03526549
The ClinicalTrials.gov registry entry for NCT03526549 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 483 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 76-participant average among 5 other Cellulite trials with a reported enrollment target (536% higher). The listed sponsor is Endo Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cellulite appearing as the primary indexed condition, and to 2 interventions - of which Observation is the first listed.
NCT03526549 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03526549 about?
NCT03526549 is a clinical study titled "Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)". A Phase 3b, Open-Label Extension Study to evaluate safety and how long response of EN3835 (Collagenase Clostridium Histolyticum \[CCH\]-aaes) lasts in the treatment of Cellulite.
What is the current status of trial NCT03526549?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 483 participants. The study started on 2018-04-26. Estimated completion is 2021-10-08.
What conditions does trial NCT03526549 study?
This clinical trial studies the following conditions: Cellulite, Edematous Fibrosclerotic Panniculopathy.
What interventions are being tested in trial NCT03526549?
The interventions under investigation include: Observation (OTHER), CCH-aaes (BIOLOGICAL).
Who is sponsoring clinical trial NCT03526549?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03526549 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cellulite
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Minimally Invasive Active Release of Septa Bands for Cellulite and Connective Tissue Release for Fibrosis Treatment in Body Contouring Surgery
RECRUITING · NA
-
Cyrolipolysis vs Cyrolipolysis and Subcision for Cellulite
ACTIVE NOT RECRUITING · NA
-
Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks
COMPLETED · Phase 2
-
The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
COMPLETED · Phase 1
-
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.